Breaking News Headlines Today | Ground News

Black Friday Sale - Get 40% off Vantage

Arcutis Biotherapeutics image

News from Arcutis Biotherapeutics

Arcutis Biotherapeutics’s media bias is unknown. Ground News is unable to assign a bias rating and does not have ratings available from Ad Fontes Media, All Sides, and Media Bias/Fact Check.

Arcutis Biotherapeutics’s aggregated factuality score is Unknown. Factuality is assigned by combining fact check, credibility, and reliability ratings from Ad Fontes Media and Media Bias/Fact Check.

Information about Arcutis Biotherapeutics

Where is Arcutis Biotherapeutics located?Arcutis Biotherapeutics's Website

Media Bias Ratings

Do you disagree?

Edit bias

Learn more about Media Bias Ratings.

Factuality

Learn more about Factuality Ratings

Reveal Factuality Ratings by upgrading to a Premium account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Ownership

Learn more about Ownership categories

Reveal Ownership Data by upgrading to a Vantage account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Top Arcutis Biotherapeutics News

Arcutis Completes Enrollment in INTEGUMENT-INFANT Phase 2 Study Evaluating ZORYVE® ...

Arcutis Completes Enrollment in INTEGUMENT-INFANT Phase 2 Study Evaluating ZORYVE® ...

100% Center coverage: 1 sources

Investigational ZORYVE cream 0.05% was formulated for the delicate skin of infants and young children with mild to moderate atopic dermatitisTopline results anticipated in Q1 2026The U.S. FDA approved ZORYVE cream 0.05% for the treatment of mild to moderate atopic…See the Story

Roflumilast sNDA Accepted for Plaque Psoriasis in Patients 2 to 5 Years

Thousand Oaks · Thousand Oaks

Roflumilast sNDA Accepted for Plaque Psoriasis in Patients 2 to 5 Years

A Prescription Drug User Fee Act target action date is set for June 29, 2026.See the Story

Breaking News Topics Related to Arcutis Biotherapeutics